2012 Fiscal Year Final Research Report
The establishment of drug sensitivity systems targeting breast cancerstem cells
| Project/Area Number |
22591441
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Iwate Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
UESUGI Noriyuki 岩手医科大学, 医学部, 講師 (10291618)
WAKABAYASHI Gou 岩手医科大学, 医学部, 教授 (50175064)
INABA Tooru 岩手医科大学, 医学部, 助教 (60405800)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Keywords | 癌幹細胞 / 細胞・組織 / 薬物反応性 |
|---|
| Research Abstract |
At first, we planed to investigate the chemotherapy- sensitivity test using primary breast cancers, metastatic lymph node and bone marrow. Then primary samples and metastatic lymph nodes were investigated using immunohistochemistry to confirm the differences between these about stemness as ALDH1 positivity. After this experiments, we found that stemness and also EMT（Epithelial-Mesenchymal transition）related proteins, i.e. TWIST, SNAIL, Vimentin、E-cadherin、β-catenin were identified in metastatic lymph node than primary tumors. Therefore, we proceeded these focusing on primary tumor with lymph vascular invasion as a suspected phenotype which has EMT features. After all, we identified EMT markers were frequently located in tumor boundary than center, and EMT marker positive patients tend to be worse prognosis than negative. The core functions of EMT should be cell mobility, and also it might be change of sensitivity of cytotoxic drugs in which were developed for differentiated cancers. These hypotheses are met to initial aims to clarify the new system about cytotoxic drugs sensitivity test. These initial, but very important findings were presented in several meeting, and a manuscript is under the review and revise.
|
